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Abstract 
Maturity onset diabetes of the young (MODY) is caused by single gene mutations that 
are of autosomal dominant inheritance. Mutations are highly penetrant, and patients 
often develop a phenotype similar to type 1 or type 2 diabetes. Glucokinase, Hepatic 
nuclear factor 1a and 4a mutations consists of 80% of MODY cases. Approximately 1% 
of patients with diabetes have MODY, and it is often misdiagnosed. Diagnosis is 
important as patients with MODY often have a good prognosis and glycaemic control if 
they are treated appropriately. The aim of this thesis was to explore the use of islet 
autoantibodies, in particular a new autoantibody against Zinc Transporter 8, as 
biomarkers to identify MODY. 
A literature review of MODY and its important subtypes are discussed. It highlights the 
major mutation that cause MODY and the management of patients with MODY is also 
explored. Islet autoantibodies will also be reviewed in the same chapter, with a 
discussion on established autoantibodies and ZnT8 autoantibodies in relation to type 1 
diabetes. 
Chapter 1 aims to investigate whether ZnT8 autoantibodies are similar to established 
autoantibodies against GAD and IA-2 as a biomarker in differentiating T1D patients 
from MODY patients. The prevalence of ZnT8 autoantibodies in MODY patients and 
the effect of disease duration on antibody prevalence and discriminative power would 
also be investigated.  
In Chapter 2, a study was performed to investigate whether islet autoantibodies are 
useful in the MODY referral setting in ruling out patients for genetic testing. This is a 
way to rationalise genetic testing at the Exeter molecular genetics referral service. 
Additionally, other biomarkers will also be investigated, namely C-peptide levels and 
Type 1 Diabetes Genetic Risk score. Results from the study will have implications to 
how MODY is diagnosed at the referral service. 
A discussion of the findings of each chapter, implications and plans for future research 
will be explored in chapter 3. 
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Structure of thesis 
The aim of this thesis is to investigate whether autoantibodies against ZnT8 
(ZnT8A) is a useful biomarker in the diagnosis of MODY. This will be 
investigated alongside established antibodies against glutamic acid 
decarboxylase (GADA) and protein tyrosine phosphatase islet antigen-2 (IA-
2A). 
The introduction is a review of MODY and islet autoantibodies. The first part 
discusses the clinical features, diagnosis and treatment of MODY. The second 
part provides an overview on GADA and IA-2A, their relationship with disease 
activity in type 1 diabetes, and how they are measured. ZnT8A will also be 
reviewed, discussing the importance of ZnT8 in insulin secretion and the current 
understanding of ZnT8A on T1D disease activity. 
Chapter 1 
The next chapter aim to explore the clinical utility of ZnT8A in MODY diagnosis. 
It had been shown that patients with MODY have low prevalence of established 
islet autoantibodies, namely GADA and IA-2A. The results from the previous 
study show that islet autoantibodies can be used as rulling out test, i.e, the 
chance of a patient having MODY with a positive antibody test is low.ZnT8 
autoantibody is a relatively new test compared to established antibodies, and its 
clinical utility in differentiating T1D from MODY patients is unknown. 
The aim of this chapter is to study the prevalence of ZnT8A in patients with 
MODY and whether they are able to discriminate T1D from MODY patients 
compared to GADA and IA-2A in a case control study. 
Chapter 2 
Although islet autoantibodies had been shown to have clinical utility in 
discriminating T1D from MODY patients, previous studies were performed in a 
retrospective case control setting. In this chapter we aim to investigate whether 
islet autoantibodies are useful in ruling out patients from molecular genetic 
testing in the referral setting. A consecutive patient cohort taken from the Exeter 
molecular genetics referral service is studied, with islet autoantibody levels 
compared between MODY patients and patients without a genetic diagnosis. 
Although not the main focus of the chapter, the clinical utility of other 
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biomarkers, such as C-peptide and the type 1 diabetes genetic risk score, was 
also investigated. 
Chapter 3 
The major findings from the previous two chapters are discussed, along with the 
strength and limitation of the study, clinical implication and future research 
within the area. 
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Maturity Onset Diabetes of the Young 
and Islet Autoantibodies 
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1 – Maturity Onset Diabetes of the Young (MODY) 
1.1 – Biology of MODY 
Maturity Onset Diabetes of the Young is characterised by a monogenic mutation 
causing a familial, non-insulin dependent diabetes mellitus. The clinical 
description of the first distinct cases by Tattersall in 1920s found that these 
patients often have disease of autosomal dominant inheritance. Patients 
described in the original cohorts were a mixture of young-onset and maturity-
onset diabetes, and therefore the term maturity onset diabetes of the young was 
coined at the time (1). 
In recent years, new molecular genetic techniques allowed the identification of 
genes that are involved in the pathogenesis of MODY. It is now known that 
MODY is caused by single gene mutations that are highly penetrant which leads 
to a diabetic phenotype. Over 10 different genetic mutations have been 
identified since Tattersall’s discovery of the disease, and the classification of 
gene mutations enabled further understanding of the phenotypes and clinical 
characteristics caused by MODY-related mutations. This includes the age of 
onset, level of hyperglycaemia, complications, and treatment prognosis. The 
most common MODY genotypes includes heterozygous mutations of 
glucokinase (GCK) gene, hepatocyte nuclear factor 1a (HNF1a) and hepatocyte 
nuclear factor 4a (HNF4a), which accounts for 80% of MODY cases (2). 
Patients with these mutations have differing clinical characteristics, with 
different responses to treatment. 
 
1.2 – Glucokinase (GCK) 
Mutation to the glucokinase (GCK) gene disrupts the beta cells’ ability to sense 
glucose at normal homeostatic levels. GCK is an enzyme that allows the 
phosphorylation of glucose to glucose-6-phosphate after its entry into the beta 
cell through the GLUT-2 channel. Glucose-6-phosphate undergoes glycolysis 
and metabolised into pyruvate, which enters the citric acid cycle within the 
mitochondria for the production of ATP. Increasing levels of ATP closes ATP-
dependent potassium channels and opens voltage-gated calcium channels, 
causing an influx of calcium (3,4). This triggers insulin exocytosis into the 
luminal space. In many ways, GCK acts as a “glucose sensor” for insulin 
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exocytosis as it controls the amount of glucose-6-phosphate that enters the 
insulin exocytosis pathway (5). 
 
 
 
 
 
 
 
 
 
 
 
 
A heterozygous loss of function mutation of GCK results in decreased levels of 
glucose phosphorylation within the beta cell, which have effects on insulin 
exocytosis. Compared to the beta cell in normal individuals, patients with GCK 
mutations require a higher glucose threshold before insulin exocytosis is 
triggered. Previous studies have demonstrated a decrease in insulin secretion 
rates over a normal glucose range of 5-9 nmol and reduced sensitivity to 
glucose in the beta cells of patients with heterozygous GCK mutations (6). 
Figure 1: A diagram representing insulin secretion within the beta cell. Glucose enter the beta 
cell through the GLUT2 transport. Glucose then undergoes phosphorylation by GCK into 
Glucose-6-phosphate and enters the glycolytic pathway which forms pyruvate. Pyruvate enters 
the citric acid (Kreb’s) cycle in the mitochondria, leading to production of adenosine triphosphate 
(ATP). Increasing ATP closes ATIP-sensitive potassium channels, leading to the depolarisation 
of the beta cell membrane and an influx of calcium ions within the cell, which triggers insulin 
exocytosis. The most common genetic mutations occur in the GCK gene and HNF1a and HNF4a 
genes within the beta cell nucleus. (Reproduced from McDonald TJ, Ellard S. Maturity onset 
diabetes of the young: identification and diagnosis. Ann Clin Biochem. 2013 Sep 1;50(5):403–
15.) 
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Patients with heterozygous mutations of GCK presents with a mild 
hyperglycaemia of 5.5 – 7.5 mmol with minimal symptoms. Glycated 
haemoglobin (Hba1c) levels are usually fairly constant and vascular 
complications are rare, even in patients with longstanding disease. Due to these 
characteristics, patients with GCK mutations are often diagnosed incidentally 
with a higher than normal Hba1c test (3,7). Although clinical symptoms of these 
disease are mild without further sequelae (8), it is important to diagnose GCK-
MODY correctly. Clinicians may treat patients with GCK-MODY unnecessarily 
with insulin or OHA if they misdiagnosed them as having type 1 or type 2 DM, 
which carries unnecessary side effects. This is especially true in younger 
populations, where type 1 DM is prevalent.  
1.3 – Hepatic nuclear factor 1a (HNF1a) 
In contrast to GCK-MODY, mutations to HNF1a causes longstanding diabetes 
mellitus associated with vascular complications. HNF1a is a transcription factor 
that is important in the expression of genes during embryonic development, and 
it is expressed in the pancreas, kidneys and intestines (9). In the mature beta 
cell, HNF1a is important in beta cell development and the secretion of insulin. 
Animal models with HNF1a mutations showed reduced gene expression 
affecting glucose transport within the beta cell, with reduced expression of 
insulin (9,10). The gene is localised in chromosome 12, with the mutation being 
highly penetrant (11). 
Patients with HNF1a-MODY have slightly different clinical characteristics 
compared with GCK-MODY. These patients tend to be normoglycaemic at birth, 
with lower BMI and lower prevalence of hypertension compared to patients with 
type 2 diabetes. They are also diagnosed younger, with median age of 
diagnosis under the age of 25 years old (3,7). Unlike MODY caused by GCK 
mutations, patients with HNF1a mutations tend to develop microvascular and 
macrovascular complication from poor glycaemic control due to continuing 
decline of beta cell function and decreasing insulin levels (12). Patients with 
HNF1a mutations often have symptoms of diabetes and are usually non-insulin 
dependent, with persistent C-peptide production of more than 200 umol even 
after the honeymoon phase of 3 years (7,13). 
Although HNF1a-MODY carries serious complication and disease burden, 
patients with the disease shows marked response to sulphonylureas, an oral 
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hypoglycaemic agent. It had been shown in case reports that patients with 
HNF1a were sensitive to the effects of sulphonylureas (14). Further randomised 
crossover trials had shown that patients with HNF1a-MODY had a 5.2 fold 
greater response than to the biguanide metformin compared to patients with 
type 2 DM (15). The proposed mechanism of such a response had been 
attributed to the nature of the defects seen in HNF1a mutations. Mouse models 
with HNF1a mutations had been shown to have decreased insulin release and 
impaired glucose metabolism, due to decrease ATP production. Sulphonyureas 
bind to the ATP sensitive potassium channels, leading to the closure of the 
channel and calcium influx into the beta cell, ultimately causing insulin release. 
As the problems caused by HNF1a mutation and ATP production are higher 
upstream in the insulin release pathway, sulphonylureas bypasses these 
problems to facilitate insulin release (15). Interestingly, patients who had 
previously been on longstanding insulin can be switched to sulphonylureas 
without further complications, although some patients with long standing 
diabetes may require insulin therapy (16). 
As sulphonylureas are shown to be effective, it is vital not to misdiagnosis 
HNF1a-MODY. It is recommended that patients with HNF1a-MODY be put on a 
low dose of sulphonylurea, for example, gliclazide, at a dose of 20 – 40 mgs per 
day (3,7).  
1.4 – Hepatic nuclear factor 4a (HNF4a) 
HNF4a forms part of a network of transcription factors within the beta cell, along 
with HNF1a-MODY, therefore patients with HNF4a-MODY present similarly as 
patients with HNF1a-MODY. Like HNF1a-MODY, patients with HNF4a-MODY 
often present before the age 25 years old, although a portion of patients do 
present at a later age (3). There is a good treatment response to 
sulphonylureas in patients with HNF4a-MODY, therefore a low dose 
sulphonylurea is recommended in the treatment of HNF4a-MODY.  
Additionally, it is important to diagnose HNF4a-MODY correctly as it may 
complicate the management of pregnancy. HNF4a mutations was found to be 
associated with macrosomia, with a median birthweight increase of 790g in 
patients with HNF4a-MODY (17). Transient hypoglycaemia has also been 
observed in patients with HNF4a mutations (17). These are important features 
15 
 
of HNF4a-MODY as they may complicate the perinatal period of patients with 
the disease. 
 
 
1.5 – Other forms of MODY 
HNF1b-MODY is caused by a rarer mutation of the HNF1b gene leading to a 
distinct form of MODY. Similar to HNF1a and HNF4a, HNF1b form part of the 
transcription factors within the beta cell. HNF1b is expressed in a wide range of 
organ, including the pancreas and kidneys. There is variable penetrance with 
HNF1b, and family history may not always be present as de novo mutations had 
been found to be present in up to 50% of patients (18–20). Unfortunately, the 
benefits of sulphonylureas are not seen in patients with HNF1b-MODY, with 
patients experiencing hyperinsulinaemia and insulin resistance. Although 
patients usually require insulin therapy, insulin requirement is usually low (21). 
Genetic Mutation Function Key characteristics Treatment 
Glucokinase 
(GCK) 
Phosphorylates 
glucose to form 
glucose-6-phosphate 
 Mild hyperglycaemia of 5.5 – 7.5 
mmol with minimal symptoms 
 Stable HbA1c with levels < 7.5%  
 Minimal complications of diabetes 
Rarely requires 
treatment 
Hepatic Nuclear 
Factor 1a (HNF1a) 
Transcription factor of 
pancreatic beta cells 
 Poor glycaemic control due to 
decline of beta cell function  
 Persistent fasting C-peptide 
production 
 Microvascular and 
macrovascular complications 
Sensitive to 
sulphonylureas 
Hepatic Nuclear 
Factor 4a (HNF4a) 
Transcription factor of 
pancreatic beta cells 
 Similar to MODY caused by 
HNF1a mutations 
 Associated with macrosomia and 
transient neonatal hypoglycaemia 
Sensitive to 
sulphonylureas 
Table 1: Summary table of key characteristics of most common subtypes of MODY 
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Although HNF1b is closely related to HNF1a and HNF4a, there are some 
distinct clinical characteristics seen in HNF1b-MODY. As HNF1b is important in 
the development of the pancreas and beta cell function, patients with HNF1b 
mutation had been shown to have pancreatic atrophy, mild exocrine 
insufficiency and low birth weight (20). HNF1b is a rare cause of neonatal 
diabetes, and due to the fact that HNF1b affects early foetal development and is 
expressed in multiple organs, extra-pancreatic features are often seen. The 
most common extra-pancreatic manifestation of HNF1b-MODY is a syndrome 
of Renal Cysts and Diabetes. This affects the patients’ renal function 
significantly, and only 6% of HNF1b-MODY patients will have normal renal 
function (19). 
Besides from HNF1b-MODY, other rarer forms of MODY had been identified. 
They impact the function of the beta cell in different ways, from beta cell 
development regulated by the transcription factor IPF1 (22) to the mis-folding of 
insulin seen in INS-mutation MODY (23).  
1.6 – Importance of diagnosis 
Although the prevalence of MODY is low, accounting for 0.6% to 2% of all 
diabetes cases, it is important to attain the correct diagnosis as the right 
treatment can improve outcomes. Patients with GCK-MODY rarely requires 
treatment, and HNF1a and HNF4a-MODY can be well managed on low dose 
sulphonylurea. This means that patients can avoid unnecessary insulin 
treatment. It has been shown that patients with MODY can switch from insulin to 
sulphonylureas with no deterioration glycaemic control (24). Qualitative studies 
suggests that MODY patients felt fearful and anxious when they switched from 
insulin therapy to low dose sulphonylureas, which was possibly due to anxiety 
surrounding the treatment change and the patient’s reliance on insulin therapy 
(25). This further supports the need to improve diagnosis of patients with 
suspected MODY to avoid unnecessary insulin therapy. Furthermore, family 
members of MODY patients are at greater risk of developing MODY due to the 
nature of the disease. Early identification and management of MODY can 
reduce the development of microvascular and macrovascular complications that 
could arise from HNF1a and HNF4a-MODY. 
17 
 
2 – Diagnosis of MODY and the use of islet autoantibodies  
Although the recent advances in molecular genetics have made testing more 
accessible, it is still expensive. Molecular genetic testing remains the gold 
standard for the diagnosis of MODY in the form of Sanger sequencing and more 
recently Next Generation Sequencing. However, these techniques are still 
labour intensive as the results requires expertise to interpret (26). Therefore, 
potential biomarkers should be used to aid the diagnosis of MODY, such as islet 
autoantibodies. As MODY is a disease of genetic aetiology, patients with MODY 
are not expected to have positive islet autoantibodies. As such, islet 
autoantibodies can be used as a way to exclude patients from a diagnosis of 
MODY. It had been shown previously that the prevalence of established 
autoantibodies against glutamic acid decarboxylase (GADA) and protein 
tyrosine phosphatase islet antigen-2 (IA-2A) in MODY patients were low, with 
positivity rates being similar to control populations (<1%). GADA and IA-2A 
were also able to differentiate T1D patients from MODY patients, with a 
combined autoantibody sensitivity and specificity of 99% and 82% respectively 
(27).  Patients with positive islet autoantibodies can be ruled out from genetic 
testing as the chance of them having MODY is increasingly low.  
2.1 – Background of Islet autoantibodies 
Islet autoantibodies are a hallmark of Type 1 diabetes, and since their 
discovery, had formed an essential part of diabetes mellitus diagnosis and 
classification. Autoantibodies are antibodies created by the immune system that 
targets self-antigens. In health, the immune system is trained to recognise self-
antigens and direct antibodies against foreign, unrecognised antigens. In type I 
diabetes mellitus (T1D), autoantibodies are directed against beta cells within the 
islets of Langerhans of the pancreas. Infiltration of cytotoxic T-cells and 
macrophages contributes to the destruction of the beta-cells, leading to cell 
death and insulin deficiency (28,29). As a result, patients experience symptoms 
of hyperglycaemia, polyuria and polydipsia, along with micro and macrovascular 
complications. The discovery of islet autoantibodies allowed us to further our 
understanding of the disease and allow the classification of diabetes 
2.1.1 – Islet cell cytoplasmic antibodies (ICAs) 
First discovered by Botazzo et al in 1974, Islet cell cytoplasmic autoantibodies 
(ICAs) was the first islet antibody that demonstrated autoimmunity basis in type 
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I diabetes. Botazzo performed a study looking at patients with diabetes mellitus 
along with multiple endocrine deficiencies associated with organ-specific 
autoimmunity, including patients with Addison’s disease, Hashimoto’s thyroiditis 
and pernicious anaemia. Antibodies bound to human and rat pancreatic tissue 
was found, and the presence of antibodies correlated with disease activity in 
patients requiring insulin (30). These antibodies were later known as ICAs. 
Although ICAs were the first antibodies to be identified, they were difficult to 
quantify and measure as they bound non-specifically to human islet tissue. 
Other groups went on to study the components of ICAs (cite). Although studies 
have shown that ICAs can predict the development T1D (31), other antibodies 
have superseded the use of ICAs in the investigation of DM. 
2.1.2 – Glutamic acid decarboxylase antibodies (GADA) 
Autoantibodies against a 65kDa isoform of glutamic acid decarboxylase 
(GAD65) was discovered in 1990 as a major autoantigen. It was observed that 
some patients with a rare disease called stiff-man syndrome also seemed to 
have T1D. Patients with stiff-man syndrome have measurable GAD antibodies 
(GADA) (32). Baekkeskov et al used [35S]-methionine labelled rat islets and 
sera from patients with stiff-man syndrome to study antibodies involved in the 
disease process. They found that antibodies within the sera cross-reacted with 
the pancreatic islet tissue (33). This effectively demonstrated that 
autoantibodies seen in patients with T1D was essentially GADA within the 
pancreas. 
GAD65 seemed to be expressed within neurone and the pancreas. It catalyses 
a reaction which leads to the formation of gamma-aminobutyric acid (GABA), 
which had been shown to be important in beta cell signalling and autocrine 
functions. Experiments showed that blocking GABA receptors in human islets 
inhibited insulin secretion, suggesting a link between GABA and B-cell 
signalling (34). Although GABA is known for its inhibitory functions, especially 
within neurone, it had been shown that activating GABA channels within the 
pancreas causes an influx of chloride within the beta cell, leading to cell 
depolarisation and insulin secretion (34). 
The presence of GADA are closely related to disease activity of T1D. Studies 
found that GADA was measurable even in young patients with newly diagnosed 
T1D (35). This was support by later studies, which found that GADA were found 
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in two thirds of children with newly diagnosed T1D within the Finnish Paediatric 
Diabetes register (36). Studies also show that titres of GADA in patients with 
positive antibodies predicted subsequent antibody positivity (37). 
GADA is widely measured as part of the diagnostic workup for T1D. Assays 
have been developed and investigated in international laboratory workshops 
such as the Islet Autoantibodies Standardisation Programme (IASP) (formerly 
known as the Diabetes Autoantibodies Standardisation Programme). 
Traditionally, GADA measured in radioimmunoassay (RIA) format achieved the 
highest sensitivity (77%), specificity (95%) and diagnostic utility (ROC AUC = 
0.93) (38). In later IASPs, enzyme linked immunosorbent assay (ELISA) format 
of the test improved and achieved similar diagnostic value and utility compared 
to RIA formats (39). 
2.1.3 – Protein tyrosine phosphatase islet antigen-2 antibody (IA-2A) 
An antibody that was targeted a protein tyrosine phosphatase-like protein was 
discovered in subsequent years after the discovery of GADA. The antibody was 
isolated in cloning complementary DNA (cDNA) fragments in the sera of 
patients with insulin-dependent diabetes (40). Sequencing of the protein found 
that it was closely related to the enzyme protein tyrosine phosphatase (PTP), 
but did not show any PTP enzymatic activity. The molecule was subsequently 
named PTP islet antigen-2 (IA-2). Like GAD65, IA-2 mRNA seemed to be highly 
expressed in both brain and pancreatic tissue. Experiments suggest that IA-2 is 
important in insulin secretion (41), however further studies need to be 
performed to investigate its functions. 
IA-2 antibodies (IA-2A) are highly related to disease activity in T1D. A study 
investigating islet autoantibodies prevalence in childhood onset T1D found that 
IA-2A was present in 75% of cases studied. They also found that the risk of 
developing T1D was highly related to the number of positive autoantibodies 
(35). Interestingly, IA-2A levels were significantly higher in younger patients 
compared to older patients with T1D. This is in contrast to GADA, where the 
reverse is true, and the prevalence of GADA increased with disease duration 
(35). IA-2A positivity had also been shown to predict future T1D. In non-affected 
siblings of patients with T1D, there was more progression to diabetes in the 
presence (58%) than in the absence of IA-2A (10%) (42). This reiterates the fact 
that IA-2A is closely related to T1D disease activity. 
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Due to the relationship between IA-2A and disease activity, it had been used as 
a marker of disease activity. Like GADA, assays had been developed to 
measure IA-2A, and this was investigated in IASP. IA-2A assays achieved a 
median sensitivity of 57% and specificity of 99% in the first IASP if measured in 
a RIA format, with relatively good diagnostic utility (ROC AUC = 0.77) (38). 
ELISA format of the test, like GADA, did not perform as well originally, however 
subsequent IASP workshops found that ELISA methods improved over time, 
with ROC-AUC increased from 0.81 to 0.85, similar to RIA assays, albeit with a 
slightly lower sensitivity (65% vs 70%) (39). Due to its high specificity, IA-2A is a 
useful test in evaluating patients with possible T1D. 
2.2 – Zinc transporter 8 antibody (ZnT8) 
2.2.1 – Background history and discovery 
More recently, antibodies against the cation efflux channel Zinc transporter 8 
(ZnT8) was identified as a potential target involved in the autoimmunity of T1D. 
ZnT8 antibodies (ZnT8A) were discovered after screen looking for possible 
autoantigens in the sera of newly diagnosed T1D patients and pre-diabetic 
populations. Due to the fact that ZnT8A were present in sera of patients with 
T1D who otherwise had negative GADA and IA2A, it was suggested that ZnT8A 
were an independent marker of T1D (43).   
2.2.2 – ZnT8 receptor function 
ZnT8 regulates the levels of zinc within the beta cell, which is essential to 
eventual insulin secretion. ZnT8 belongs to a family of cation efflux channels 
that is expressed throughout human tissue. Currently two families of zinc 
transporters had been identified, ZnT and Zrt-, Irt-like proteins (ZIP), with at 
least 10 members in the ZnT family (44,45). ZnT8 is solely expressed in the 
pancreas, and allows the efflux of zinc into secretory granules within the beta 
cell containing insulin (46).  
Zinc performs special functions within the beta cell, and its interaction with 
insulin is vital for insulin storage and secretion. After insulin is cleaved from 
proinsulin, it is stored in granules as monomers and dimers within the beta cell. 
Zinc transporter 8 causes the efflux of zinc into the luminal space, which is 
essential to the eventual secretion of insulin. Zinc interacts with insulin to form 
Zn-insulin hexamers, leading to crystallisation of insulin (46). These hexamers 
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are less soluble and less prone to enzymatic breakdown, which allows the 
insulin to stay in a relatively stable state during storage. Storing insulin in such a 
way increases the storage efficiency of insulin within secretory granules. As 
insulin is secreted, zinc is co-secreted, which decreases hepatic insulin 
clearance, prolonging the activity of insulin.  
2.2.3 – Measurement of ZnT8A 
Similar to GADA and IA-2A, ZnT8A assays were developed and its efficacy was 
investigated. The first IASP workshop that investigated ZnT8A assay efficacy 
was held in 2007, with participating laboratories using a RIA method to measure 
ZnT8 antibodies. This achieved a median sensitivity of 55%, a specificity of 99% 
and a relatively good diagnostic utility. Assays were improved during the second 
IASP in 2009, achieving higher sensitivity (63%) with similar specificity to the 
previous tests. Recently, commercially available ELISA systems had been 
manufactured to measure ZnT8A, and this achieved similar sensitivity and 
specificity compared to RIA methods (47).  
2.2.4 – Relation to disease activity and progression 
As ZnT8 is solely expressed in the beta cell, ZnT8A is closely related to disease 
activity due to its tissue specificity. ZnT8A correlated weakly with levels of IA-2A 
but not insulin antibodies and GADA. The same study group looked at ZnT8A 
levels in samples of first-degree relatives of T1D patients and individuals from 
the general population with a high-risk HLA genotypes for T1D and found that 
ZnT8A levels preceded the development of T1D by many years (43). 
Study of patients with new onset T1D with 2.5 year follow up 6 weeks after 
diagnosis compared to a cross-sectional study group of patients with 
longstanding diabetes revealed that ZnT8A were present at the time of 
diagnosis. Interestingly, similar to IA-2A, ZnT8A titres decreased progressively 
alongside C-peptide levels, suggesting a weaning of autoimmunity, possibility 
due to the decreasing number of beta cells within the pancreas (48,49). ZnT8A 
also demonstrated low persistence over time. Patients with longstanding T1D 
also had lower levels of ZnT8A compared to patients with recent onset disease. 
However, although the same study illustrated an statistically significant inverse 
relationship between antibody levels and age of onset, the correlation between 
two variables are weak (r2 = 0.02) (48).  
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As islet autoantibodies are associated with disease activity in T1D, they are 
useful in aiding the diagnosis of T1D in cases were the diagnosis is uncertain. 
Patients with T1D often have multiple antibody positivity at diagnosis. It had 
previously been shown that around 70% of patients with T1D would have three 
to four positive islet autoantibodies at the time of diagnosis, with less than 10% 
of patients having only one positive islet antibody positive (35,50). The 
association of islet autoantibodies with T1D can help to classify patients into 
subtypes of diabetes especially close to diagnosis. Since a positive islet 
autoantibody test point towards a diagnosis of T1D, it can theoretically be used 
as a test to rule out other forms of diabetes, such as T2D or MODY. 
3 – Biomarkers to aid the diagnosis MODY 
As mentioned, GADA and IA2A can be used as a way to exclude patients from 
a diagnosis of MODY. However, ZnT8A had recently been discovered, and its 
prevalence in MODY patients and its clinical utility in discriminating T1D and 
MODY is unknown. It would be of interest to study ZnT8A in relation to GADA 
and IA-2A as they may be helpful in the diagnosis of MODY. 
Besides from islet autoantibodies, other biomarkers are known to be useful in 
the diagnosis of MODY. These include the Type 1 diabetes genetic risk score 
(T1D-GRS), Connecting peptide (C-peptide), high density lipoprotein (HDL) and 
high sensitive C-reactive protein (HsCRP), which have been shown to aid the 
diagnosis of MODY (51–53). Most studies investigating these biomarkers were 
performed in retrospective case control studies, and have shown good 
diagnostic utility in discriminating T1D / T2D from MODY. However, no data is 
available on the diagnostic utility of these biomarkers in a prospective setting. 
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4 – Aims and Objectives 
The aim of this thesis is to investigate whether ZnT8A is a useful biomarker in 
the diagnosis of MODY. This will be investigated alongside established 
antibodies GADA and IA-2A. 
The main objectives are: 
1. To assess the prevalence of ZnT8A in patients with genetically confirmed 
MODY compared to patients with T1D. The prevalence of ZnT8A will 
also be compared to the prevalence of GADA and IA-2A in both groups. 
This will be carried out in a retrospective case control study.   
2. To assess the diagnostic utility of GADA, IA-2A and ZnT8A in 
discriminating non-MODY patients from MODY patients in a referral 
setting. The diagnostic utility of other biomarkers, namely C-peptide and 
T1D-GRS, would be investigated within this study. This will be 
investigated in a prospective cohort study. 
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1 – Islet Autoantibodies 
1.1 – GADA and IA-2A measurements: 
Samples were measured at the Academic Department of Blood Sciences at the 
Royal Devon and Exeter Hospital. GADA and IA-2A were measured using 
ELISA assays on a Dynex DS2 automated ELISA system. The positivity of titres 
cut offs were determined after testing control patients (n = 1559) Control 
subjects were between the age of 18 and 75, did not have a diagnosis of 
diabetes, and had an Hba1c of 6.0%. Islet autoantibodies were considered 
positive if titre levels were above the 99th centile of the control samples. 99th 
centile cutoff for GADA is 64 WHO units/mL and IA-2A is 7.5 WHO units/mL. 
1.2 – ZnT8A measurements: 
Samples were measured similar to GADA and IA-2A using the ELISA method 
above. Titre cutoffs were defined differently as there were differences in ZnT8 
antibody titres between control subjects at different sets of age groups. An age 
specific cut off was applied to ZnT8A titre measurements. ZnT8A were 
considered positive if levels were above the 99th centile at age specific cutoffs. 
99th centile cutoff for ZnT8A is 126 WHO units/mL (age < 30 years) / 20 WHO 
units/mL (age ≥ 30 years). 
2 – Type 1 diabetes genetic risk score 
The Type 1 diabetes genetic risk score (T1D-GRS) was measured in the study 
within Chapter 4. The score was computed using the number of risk alleles 
across 30 common T1D single nucleotide polymorphisms (SNPs), with variants 
from both HLA and non-HLA loci. They were selected based on variants that 
were strongly associated with T1D as described in existing studies.  Each 
variant was weighted based on their effect on T1D genetic risk from previous 
literature. A GRS was generated as the sum across SNPs of the number of risk 
increasing alleles (0, 1 or 2) at that SNP multiplied by the ln(odds ratio) for each 
allele divided by the number of alleles (cite). The HLA-DR3 and HLA-DR4 
haplotypes were weighted using imputed haplotypes. The sum of the score 
signifies a person’s risk for T1D. Genotyping of SNPs was performed using the 
KASP assay by LGC Genomics (Hoddesdon, UK). 
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3 – C-peptide measurement 
Serum C-peptide was measured in the study within Chapter 4. C-peptide 
analysis was performed using the Roche Modular Analytics Cobas 601 
immunoassay analyser (Roche Diagnostics, Mannheim, Germany). An antigen-
antibody-antigen sandwich complex was formed by reacting one biotinylated 
anti-C-peptide specific monoclonal mouse antibody and a second monoclonal 
antibody to Cpeptide labelled with a ruthenium complex with 20uL serum 
sample of C-peptide. Separation is achieved via interaction of biotin and 
streptavidin attachment to paramagnetic microparticles (solid phase). The 
detection system employs electrochemiluminescence with ruthenium 
trisbipyridyl as the label. Electrochemiluminescence occurs at 620 nm and 
readings are taken by the photomultiplier tube (PMT). The intensity of light 
signal is proportional to the concentration of C-peptide in the serum. The assay 
was calibrated using Roche C-peptide CalSet calibration material (Roche 
Diagnostics, Mannheim, Germany), traceable to WHO International Reference 
Reagent (IRR) for C-peptide of human insulin for immunoassay (IRR code 
84/510). Quality Control was performed on each day of analysis using low level 
(0.67 nmol/L) and high level (3.33 nmol/L) PreciControl MultiAnalyte. 
4 – MODY genetic sequencing 
Genomic DNA was extracted from whole blood using standard procedures and 
the promoter, all coding regions and intron/exon boundaries of the GCK, 
HNF1A and HNF4A genes were amplified by PCR. Amplicons were sequenced 
using the Big Dye Terminator Cycler Sequencing Kit v3.1 (Applied Biosystems, 
Warrington, UK) according to manufacturer’s instructions and reactions were 
analysed on an ABI 3730 Capillary sequencer (Applied Biosystems, Warrington, 
UK). Sequences were compared with the reference sequences (NM_000162.4 
for GCK, NM_000545.6 for HNF1A and NM_175914.4 for HNF4A) using 
Mutation Surveyor v5.0.1 software (SoftGenetics, State College, PA). 
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Abstract 
 
Introduction: Antibodies against 65 kilodalton isoform of glutamic acid 
decarboxylase (GAD) and protein tyrosine phosphatase-related islet antigen-2 
(IA-2) have previously been shown to be useful tests in differentiating Type 1 
Diabetes (T1D) from MODY. Zinc transporter 8 antibody (ZnT8A) is a relatively 
new islet autoantibody, and its clinical utility in differentiating T1D from MODY 
has not been described. The aim of this study was to determine the prevalence 
of ZnT8A in a cohort of patients with genetically confirmed MODY and to 
investigate whether ZnT8A can be used to differentiate MODY from T1D and 
the additive value above established islet antibodies GADA and IA-2A. 
 
Method: GADA, IA2A and ZNT8A were measured in 997 individuals, with 294 
(29.6%) patients having genetically confirmed MODY and 703 (70.4%) patients 
having T1D. Antibody titre cutoffs were established at the 99th centile of 1559 
control subjects. We compared the positivity rates of antibodies between MODY 
and T1D patients. 
 
Results: ZnT8A was positive in 148/703 patients (21.1%) with T1D and 2/294 
(0.7%) patient with MODY (p<0.001). ZNT8A increased the number of 
individuals with two or more positive antibodies by 26.3% (calculated as Net 
Reclassification Improvement Index, n=36 to n=66, p=<0.0001). GADA and 
IA2A were detected in 227/703 (32.3%) and 271/703 (38.5%) T1D patients 
respectively. In patients with MODY with positive antibodies, 1/137 (0.7%) 
patients had measureable ZnT8A and 1/137 (0.7%) had measurable GADA. 
Another patient had a combination of ZnT8A and GADA. No MODY patients 
had detectable IA-2A antibodies or more than two positive antibodies. The 
prevalence of islet autoantibodies decreases as increasing disease duration. 
 
Conclusion: In conclusion, we have shown that ZnT8A prevalence is low in 
MODY patients, similar to GADA and IA-2A. ZnT8A should be used in 
conjunction with GADA and IA-2A as a routine test before molecular genetic 
testing. This should be performed closer to diagnosis preferably as this 
enhances its ability to discriminate T1D from MODY. 
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1 – Introduction 
Maturity-onset diabetes of the young (MODY) is a rare form of diabetes caused 
by highly penetrant autosomal dominant mutations in a single gene. MODY 
accounts for approximately 3% of diabetes diagnosed less than 30 years of age 
(1). The most common form of MODY results from mutations within the 
glucokinase (GCK) gene and the genes encoding transcription factors 
hepatocyte nuclear factor 1a (HNF1a) and 4a (HNF4a), together accounting for 
over 80% of MODY cases (2).  Identifying patients with MODY is important as it 
defines the appropriate treatment; patients with GCK-MODY do not require any 
treatment, whereas patients with HNF1A/HNF4A MODY are sensitive to 
sulphonylurea tablets (3, 4).  
 
Despite the clinical implication of making a correct diagnosis of MODY, there is 
a significant delay for a correct genetic diagnosis and 40% are often 
misdiagnosed and mistreated as Type 1 Diabetes (T1D) (5-7). This 
misdiagnosis is due to overlapping clinical features of MODY and T1D and 
highlights the need for tests that can aid in identifying patients with a higher 
probability of having MODY.  
 
Islet autoantibodies (GADA and IA-2A) have been shown to have utility to aid 
clinicians differentiate MODY from T1D (1, 8). The prevalence of detectable islet 
antibodies against the 65 kDa isoform glutamate acid decarboxylase (GAD65) 
and tyrosine phosphatase islet antigen 2 (IA-2A) in MODY patients is the same 
as non-diabetic populations (~1%), compared to 80-90% in T1D at diagnosis 
(8). Therefore, the presence of autoantibodies can robustly rule out MODY and 
reduce the need for genetic testing. GADA and IA-2A assays are now widely 
available to clinicians and these autoantibodies can be measured easily, 
reproducibly and with a higher sensitivity and specificity than traditional 
pancreatic islet cell antibody (ICA) (9, 10).  
 
Autoantibodies against Zinc transporter 8 (ZnT8A) is the most recent T1D 
related autoantibody to be described. It can be used to identify patients with 
T1D with sensitivity and specificity to GADA and IA-2A (11, 12). However, there 
are no studies reporting ZnT8A in MODY and the utility of ZnT8A in addition to 
GADA and IA-2A to differentiate MODY from T1D remains unknown.  
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The aim of this study was to determine the prevalence of ZnT8A in a cohort of 
patients with genetically confirmed MODY and to investigate whether ZnT8A 
can be used to differentiate MODY from T1D against established islet 
antibodies GADA and IA-2A. In addition, we aim to explore the impact of 
disease duration on the diagnostic utility of islet autoantibodies at differentiating 
MODY from T1D 
 
2 – Methods 
 
2.1 – Study design and participants: 
We conducted retrospective cross-sectional case control study of 997 
individuals, 294 patients with genetically confirmed MODY: (102 GCK, 121 
HNF1A, 57 HNF4A, 14 HNF1b) and 703 patients diagnosed with T1D. 
The Type 1 diabetes cohort (clinical diagnosis of type 1 diabetes and on insulin 
from diagnosis) were all research participants from three research studies and 
the clinical characteristics were collected during recruitment. 229 were from the 
TIGI study (IRAS 141756), 309 from DARE (REC ref 2002/7/118), 117 samples 
were from UNITED (IRAS 51251). In addition, 48 samples for patients with T1D 
were taken from the Islet Autoantibody Standardization Programme (IASP).  
We had plasma from 294 patients with genetically confirmed MODY, where 
whole-blood EDTA samples were sent for the routine genetic testing to Exeter 
Molecular Genetics Department, The Royal Devon and Exeter Hospital, UK 
from 2012 to 2015. Clinical characteristics for the MODY patients were collected 
from clinical referral form.  
2.2 – Islet autoantibodies measurement 
Analysis of islet autoantibodies (GADA, IA2A, ZNT8A) was performed by the 
Academic department of Blood Sciences at the Royal Devon and Exeter 
Hospital. We measured GADA, IA2A and ZnT8A in serum for T1D and MODY 
cohort. Serum was prepared by adding calcium chloride solution and thrombin 
to EDTA plasma to initiate clotting as described previously (8).  
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GADA, IA-2A and ZnT8A were measured using ELISA assays (RSR Limited, 
Cardiff, U.K.) on a Dynex DS2 automated ELISA system (Launch Diagnostics, 
Longfield, U.K.). Antibody titre cut-offs were established after testing 1559 
control subjects without a diagnosis of diabetes between the age of 18 and 75, 
along with an Hba1c of less than 6.0% (42 mmol/mol). Antibody results were 
considered positive if titre exceeds the 99th percentile limit of controls. The 99th 
centile for GADA is ≥ 64 World Health Organization units/mL, IA-2A ≥ 7.5 World 
Health Organization units/mL, ZnT8A ≥126 World Health Organization units/mL 
(age < 30 years) / ≥20 World Health Organization units/mL (age ≥ 30 years) ). 
The laboratory participates in the Islet Autoantibody Standardisation 
Programme. 
 
2.3 – MODY genetic sequencing 
Genomic DNA was extracted from whole blood using standard procedures and 
the promoter, all coding regions and intron/exon boundaries of the GCK, 
HNF1A and HNF4A genes were amplified by polymerised chain reaction (PCR). 
Big Dye Terminator Cycler Sequencing Kit v3.1 (Applied Biosystems, 
Warrington, UK) was used to sequence amplicons. Reactions were analysed on 
an ABI 3730 Capillary sequencer (Applied Biosystems, Warrington, UK). 
Sequences were compared with the reference sequences (NM_000162.4 for 
GCK, NM_000545.6 for HNF1A and NM_175914.4 for HNF4A) using Mutation 
Surveyor v5.0.1 software (SoftGenetics, State College, PA).  
2.4 – Statistical analysis 
Antibody positivity rates were compared between MODY patients and T1D 
patients. Mann-Whitney U-test was used to determine statistical significance of 
clinical characteristics between T1D and MODY patients. Fisher’s exact test 
was used to determine the effect of single antibodies in differentiating T1D from 
MODY. Positive likelihood [sensitivity/(1 – specificity)] and negative likelihood 
values [(1 – sensitivity) / specificity] were calculated for single and multiple islet 
autoantibody positivity. Net reclassification improvement (NRI) index was used 
to compare the efficacy between established antibodies (GAD and IA2) and 
triple antibodies (GAD, IA2 and ZnT8) (13).  
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The effect of duration on antibody positivity was explored based on 25th, 50th 
and 75th centile of diabetes duration of the whole cohort. Data was cleaned 
using Stata Statistical Software: Release 14. (College Station, TX: StataCorp) 
and Rstudio (RStudio, Boston, MA). Graphs were created using ggplot2 
package within RStudio (14). 
3 - Results  
3.1 – Patient Characteristics 
Overall, patients with T1D had a higher Hba1c (median 68, interquartile range 
(IQR) 58 – 81 mmol/mol vs 50, 45 – 60 mmol/mol, p = < 0.0001) and longer 
disease duration (median 13 , IQR 5 – 25 years vs  3, 0 – 16 years, p = < 
0.0001) compared to MODY patients within this cohort. Age of diagnosis was 
similar between both groups (median 21, IQR 13 – 34 years vs 21, 16 – 31 
years, p = 0.83). 
3.2 – ZnT8 antibody prevalence in T1D and MODY close of diagnosis (<2 
years duration) 
The prevalence of ZNT8A was 50% (57/114) in T1D and 0.7% (1/137) in MODY 
patients. The prevalence of ZNT8A in patients with T1D was higher than GADA 
(50% vs 48.2%) (p = 0.7) and modestly higher than IA-2A (50% vs 66.7%) (p = 
< 0.001).   
3.3 – Additional benefit of ZnT8 islet autoantibody in T1D and MODY 
patients close of diagnosis (< 2 year duration) 
Overall 99/114 (86.8%) patients with T1D and 2/137 (1.5%) patients with MODY 
had positive islet autoantibodies. Testing of ZnT8A identified an additional 
23/721 (3.2%) of T1D patients who were previously negative for GADA and IA-
2A. In MODY patients, only 1/137 (0.7%) patient had positive ZNT8A and 1/137 
(0.7%) GADA. No MODY patients had two positive antibodies (See figure 1). 
The patient characteristics of antibody positive MODY cases for the whole 
cohort are summarised in table 1.   
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Figure 1. Bar chart showing the percentage of antibody positivity between T1D (n=114) 
and MODY (n=137) patients with disease duration less than two years 
 
Table 1. Clinical characteristics of MODY antibody‐positive patients within the whole 
cohort 
 
Genetic 
Mutation 
Positive 
Antibody Phenotype 
Initial 
Treatment 
Current 
Treatment 
Age of 
Diagnosis 
Time to 
insulin 
Hba1c 
(mmol/mol) 
C-peptide 
level 
(pmol/L) Clinical Features 
HNF4a 
p.R114W GADA Diabetic Diet 
Insulin 
(basal 
bolus) 64 N/A 69 
119 Ischaemic heart disease, 
peripheral vascular disease, 
retinopathy, and neuropathy 
HNF1b 
p.R276* GADA+ZnT8A Diabetic 
Insulin 
(basal 
bolus) 
Insulin 
(basal 
bolus) 25 
at 
diagnosis 63 
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Treated as type 1, on insulin 
throughout diabetes, stage 4 
kidney disease 
HNF1b 
p.R295H ZnT8A 
Diabetes & 
Renal Cysts 
Insulin 
(basal 
bolus) 
Insulin 
(basal 
bolus) 4 
at 
diagnosis 66 
Not 
available 
Treated as type 1, on insulin 
throughout diabetes, renal 
cysts found antenatally 
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3.4 – Differentiating MODY from T1D in short disease duration 
Negative ZnT8A had sensitivity of 99.3 % and specificity of 50.0% at 
discriminating MODY from T1D. This was similar to a negative GADA 
autoantibody test (sensitivity of 99.3% and specificity of 48.2%). The sensitivity 
and specificity of a negative IA-2A test was higher compared to ZnT8A 
(sensitivity of 100% and specificity of 66.7%). The combined sensitivity and 
specificity of GAD, IA-2A and ZnT8A is 98.5% and 86.8% respectively. The 
addition of ZnT8A antibodies increased the number of patients with two or more 
antibodies by 26.3% (calculated as NRI index, p < 0.0001) 
 
This equates to a positive likelihood ratio for identifying MODY from T1D in 
short duration disease of 7.5 for three negative antibodies and a negative 
likelihood ratio of 0.02 and < 0.0001 for one and two or more detectable 
antibodies respectively. Based on a MODY prevalence of 3% (1:33) in patients 
with diabetes diagnosed under the age of 30, this would decrease the 
probability to 1:1923 for one positive antibody, and 1:25645 for two or more 
antibodies. 
 
3.5 – The prevalence of islet autoantibody is dependent on duration of 
diabetes 
In order to assess the effect of diabetes duration on antibody positivity, we 
divided the whole cohort into quartiles of disease duration (<2 years, 2 – 10 
years, 10 – 22 years, and >22 years). We found 86.8% (99/114) of T1D patients 
with disease duration less than two years were positive for antibodies. This falls 
to 70.9 % (134/189), 52.5 % (107/204) and 42.3% (83/196) at disease duration 
between 2 to 10 years, 10 to 22 years, and >22 years respectively (see figure 
2). Antibody prevalence remains low in MODY patients, with positivity rates of 
0.7 to 1.5% across all durations.  
 
The prevalence of GADA, IA-2A and ZnT8A fell as disease duration lengthened 
in patients with T1D. The prevalence of GADA was higher in patients with 
shorter disease duration (<2 years) compared to patients with longer disease 
duration (>22 years) (48.2% to 24.5%, difference 23.7%, p= <0.0001, 95% CI 
12.6 – 34.3%). A fall in prevalence is also seen in IA-2A (66.7% to 21.4%, 
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difference 45.3%, p= <0.0001, 95% CI 34.3 – 56.3%) and ZnT8A (50% to 8.2%, 
difference 41.8%, p= <0.0001, 95% CI 31.2 – 52.5%). The prevalence of ZnT8A 
after 22 years was lower compared to GADA (8.2% vs 24.5%, p= <0.0001) and 
IA-2A (8.2% to 21.4%, p= <0.0001) (see figure 3). Subsequently, the specificity 
of islet autoantibody tests in differentiating MODY and T1D decreases in 
patients with longer disease duration, with a specificity of 86.8% and 42.3% in 
patients with < 2years and >22 years disease duration respectively.  Sensitivity 
remains similar in all groups, ranging from 97.8% to 100% and the NPV also 
remains high across all durations. 
 
  
 
 
Figure 2. Bar chart and table showing the percentage of antibody positivity between 
T1D and MODY patients and diagnostic utility by disease duration 
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Figure 3. Bar chart showing individual antibody positivity rates in patients with T1D 
across disease duration (in quartiles) 
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4 – Discussion 
ZnT8A were able to differentiate T1D patients from MODY independently, with 
sensitivity and specificity comparable to GADA and IA-2A. We have shown that 
prevalence of ZnT8A is around 1% in patients with MODY, equivalent to the 
prevalence within control populations. Although ZnT8A modestly increased the 
number of patients who were previously antibody negative, they were able to 
increase the number of patients who were positive for a single antibody to 
multiple antibody positivity by 26.3%.  
 
Maximum diagnostic utility of islet autoantibodies in differentiating MODY from 
T1D was seen close to diagnosis, with the prevalence of antibodies decreasing 
with time. This was especially true for ZnT8A and IA-2A. ZnT8A was evidently 
lowest in T1D patients with the longest disease duration within this cohort, 
compared to GADA and IA-2A, possibly due to the decreasing number of 
antigens present within the beta cell over time. It is important to note that the 
prevalence of islet autoantibodies in MODY patients remained low across 
different durations within this cohort.  
 
The three MODY patients with positive GADA and / or ZnT8A may have 
developed concomitant T1D, which was supported by their clinical 
characteristics. Firstly, the patients were insulin-dependent, and two of the 
patients required insulin at diagnosis. Secondly, the serum C-peptide levels for 
two of the patients were below 200 pmol/L, suggesting a decreased insulin 
production as seen in patients with T1D. The data here suggests the high 
likelihood that these patients may have developed T1D. Alternatively, the 
MODY patients may represent the 1% of the population with positive islet 
autoantibodies without associated pathology. 
 
This is to our knowledge the first formal study which investigated the prevalence 
and diagnostic utility of ZnT8A in MODY patients in relation to GADA and IA-2A. 
This study shows that the prevalence of islet autoantibodies, including ZnT8A, 
is low in MODY patients. Previously we have measure the serum of 500 
patients with genetically confirmed MODY (8). Along with this cohort of patients 
presented in this study, we have now measured the serum of over 800 
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individuals with MODY, and had consistently found low prevalence of islet 
autoantibodies. This reiterates the fact that islet autoantibodies do not form part 
of the disease process in classical forms of MODY. Other studies in the past, 
mainly in the form of case reports, have suggested that autoimmunity is rare in 
MODY (15-18). A study based on a German-Austrian registry cohort with 
MODY patients reported an islet autoantibody prevalence rate of 17% in MODY 
patients. However, not all patients within the registry received MODY genetic 
testing, as 20% of the patients within the registry were not tested. This meant 
that some patients could have been misclassified as having MODY. It is 
possible that autoantibody-positive patients within this registry have T1D.  
 
The strength of this study include the large cohort of MODY patients, allowing 
the examination of duration effects on the positivity rates of islet autoantibodies 
at different time points. We have also measured ZnT8A along with GAD and IA2 
and compared their prevalence between T1D and MODY patients, and the 
serum was analysed in a single laboratory. Our antibody reference ranges were 
derived from a standard control population, making our reference cut-offs 
robust. Finally, we have explored the effect of disease duration on the 
prevalence of islet autoantibodies between T1D and MODY patients within this 
study which had been impossible previously because patients were studied 
close at diagnosis. 
There are several limitations to our study. As this study was set up as a case 
control, it was a retrospective analysis of the data available. The study on the 
effects of disease duration was based on a cross-sectional analysis across the 
study cohort, meaning we were not able to study the effect of disease duration 
in the same patients over time as longitudinal data was unavailable. We also 
could not exclude the possibility that patients within this cohort were pre-
screened for antibodies before they were referred to our genetic laboratory, 
which could explain the low prevalence in our study group. However, if the 
analysis within this study was restricted to only probands (n = 183) who 
previously were not screened for autoantibodies, the antibody prevalence rate 
was 0.01%, lower than the expected prevalence in control populations 
The results of this study have several clinical implications. Since islet 
autoantibodies is a sign of autoimmunity in T1D, we would not be expected to 
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observe positive autoantibodies in patients with MODY. Therefore, islet 
autoantibodies could be considered as a “ruling out” test for patients with 
suspected MODY. The results here also show that the increasing number of 
positive islet autoantibodies decreases the probability of a MODY diagnosis, 
signifying that more islet autoantibodies should be measured when investigating 
patients with suspected MODY. This means that ZnT8A should be measured 
alongside GADA and IA-2A to increase the diagnostic utility of islet 
autoantibodies as a whole. In addition, since the maximum diagnostic utility of 
islet autoantibodies is achieved when they are measured close to diagnosis, we 
suggest that clinicians should measure islet autoantibodies as close to 
diagnosis as possible when the diabetes subtype is uncertain or if MODY is 
suspected, as this would enhance their ability in differentiating T1D from MODY. 
 
As this is a case control study, the next step would be to investigate whether 
islet antibodies are useful in the referral setting. Other biomarkers, such as 
Connecting peptide, MODY prediction model, and Type 1 diabetes genetic risk 
scores could also be investigated, which may have additive value to islet 
autoantibody before genetic testing is performed. It would also be clinically 
useful to perform a longitudinal study of T1D and MODY patients looking at the 
effects of disease duration on the prevalence of islet autoantibodies. This would 
provide a better picture on islet autoantibodies prevalence over time. 
 
In conclusion, we have shown that ZnT8A prevalence is low in MODY patients, 
similar to GADA and IA-2A. ZnT8A should be used in conjunction with GADA 
and IA-2A as a routine test before molecular genetic testing. This should be 
performed closer to diagnosis preferably as this enhances its ability to 
discriminate T1D from MODY. 
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Abstract 
Introduction: Maturity Onset Diabetes of the Young (MODY) is caused by a 
single gene mutation inherited in an autosomal dominant fashion. The disease 
comprises of 3-4% of all diabetes in patients under 30 years old. However, the 
correct genetic diagnosis is important as it defines treatment. We aimed to 
investigate if islet autoantibodies could be used as a test to rationalise MODY 
genetic testing in an NHS referral setting. In addition, we compared the 
diagnostic utility of islet autoantibodies with C-peptide and the Type 1 diabetes 
genetic risk score (T1D-GRS) both of which have been indicated as useful tests 
to rule out patients from MODY genetic testing. 
Method: Triple islet autoantibodies (GADA, IA-2A and ZnT8A) and C-peptide 
were measured on 834 consecutive patients referred for MODY testing with 
whole-blood sampled between 2012 and 2015. Positivity of islet antibodies were 
based on the 99th centile of 1500 non-diabetic controls.  Every patient had 
GCK, HNF1a and HNF4a genes sequenced. We compared the positivity rates 
of antibodies in patients with and without an established genetic diagnosis. 
Result: Islet autoantibodies were able to exclude 20.9% patients from 
unnecessary MODY genetic testing. The exclusion rate increased to 32.2% in a 
sub-analysis of patients who were on insulin treatment, i.e, 1 in 3 non-MODY 
patients could have been excluded from MODY genetic testing. There was no 
additional diagnostic utility in C-peptide and T1D-GRS in excluding patients 
from MODY genetic testing. 
Conclusion: The combination of GADA, IA-2A and ZnT8A were able to exclude 
20-30% of patients from MODY genetic testing in the referral setting. C-peptide 
and T1D-GRS were not additive on top of islet autoantibodies in excluding 
patients from genetic testing. As the measurement of islet autoantibodies was a 
cost effective way of rationalising genetic testing, it would be embedded in the 
diagnostic pathway at the genetics referral service in Exeter.  
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1- Introduction 
Maturity Onset Diabetes of the Young (MODY) is caused by a single gene 
mutation inherited in an autosomal dominant fashion. The mutation is highly 
penetrant, and phenotypically similar to more common forms of diabetes, 
namely type 1 and type 2 diabetes (T1D and T2D). Mutations of the glucokinase 
gene (GCK), hepatic nuclear factor 1a (HNF1a) and 4a (HNF4a) comprises of 
80% of MODY diagnoses (1). 
MODY is relatively rare, comprising of 3.6% of all diabetes in patients under 30 
years old (2). However, the correct genetic diagnosis is important as it defines 
treatment, patients with GCK mutations rarely require treatment, and patients 
with HNF1a and HNF4a mutations can be well managed on low dose 
sulphonylurea, with good glycaemic control (3-5). Despite this, the disease is 
often misdiagnosed, with more than 80% of patients initially being treated as 
either type 1 (T1D) or type 2 diabetes (T2D) (6). A diagnosis of MODY is 
suspected if a patient lack clinical characteristics of T1D and T2D with a family 
history of diabetes in one parent and first‐degree relatives of that affected 
parent or a mild stable fasting hyperglycemia which does not progress (5). 
Genetic testing should be considered in these patients to guide diagnosis. 
Molecular genetics remains the gold standard for the diagnosis of MODY and 
despite decreasing costs with improved technology, it is still not possible to 
implement wide spread genetic testing for MODY. The molecular genetics 
laboratory at the Royal Devon and Exeter NHS Foundation Trust is 
internationally recognised for its MODY testing service. The laboratory has 
made a genetic diagnosis in over 4000 patients over the past 20 years and 
processes over 1000 referrals for MODY testing each year. This can be an 
expensive process, and as a result, biomarkers, such as islet autoantibodies, C-
peptide, and Type 1 genetic risk score (7-9) have been investigated to help 
identify MODY in young onset diabetes and have been found to be useful in 
rationalising genetic testing. 
It is worth investigating the use of biomarkers in rationalising genetic tests in an 
atypical group of patients referred for molecular genetic testing as there are 
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clinical and financial implications. Clinically, biomarkers can be used to aid the 
diagnosis of patients with suspected MODY so that they could be correctly 
treated. Financially, it is important not to test patients who are unlikely to have 
MODY as molecular genetic testing still remains costly. 
We have previously shown that there is a low prevalence of  autoantibodies 
against GAD65 isoform of glutamate decarboxylase (GADA) and tyrosine 
phosphatase‐related protein islet antigen 2 (IA-2A) in MODY patients and its 
discriminative power in differentiating T1D patients from MODY (7). Recently, 
we showed that autoantibodies against the zinc transporter 8 (ZnT8A) can also 
discriminate T1D patients from MODY patients. However, these studies were 
retrospective case control in design, and not performed in the prospective 
referral setting. In addition, the use of other biomarkers, namely C-peptide and 
Type 1 diabetes genetic risk score (T1D-GRS), has potential use in ruling out 
patients for MODY genetic testing but their efficacy have not been investigated 
in the prospective referral setting. 
The aim of this study was to investigate if islet autoantibodies were able to 
exclude patients in the referral setting as a way to rationalise MODY genetic 
testing. In addition, we aimed to explore whether C-peptide and T1D-GRS were 
useful biomarkers along antibodies in ruling out patients from MODY genetic 
testing. 
2- Method 
2.1 Study participants 
834 consecutive patients were referred to the Exeter molecular genetics 
service, with whole blood available. Islet autoantibodies (GADA, IA-2A, ZnT8A) 
and C-peptide were measured analysed by the Academic department of Blood 
Sciences Department at the Royal Devon and Exeter Hospital. All patients had 
GCK, HNF1a and HNF4a genes sequenced. Clinical characteristics were taken 
from genetic test referral forms. Referral forms indicate whether patients had 
autoantibody tests before being referred. 
2.2 Islet autoantibodies measurement 
GADA, IA-2A and ZnT8A were measured using ELISA assays (RSR Limited, 
Cardiff, U.K.) on a Dynex DS2 automated ELISA system (Launch Diagnostics, 
Longfield, U.K). Antibody titre cutoffs were established after testing 1559 control 
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subjects without a diagnosis of diabetes between the age of 18 and 75, along 
with an Hba1c of less than 6.0%. Islet antibodies were considered positive if 
levels were above the 99th centile of the non-diabetic control subjects (GADA ≥ 
64 World Health Organization units/mL, IA-2A ≥ 7.5 World Health Organization 
units/mL, ZnT8A ≥126 World Health Organization units/mL (age < 30 years) / 
≥20 World Health Organization units/mL (age ≥ 30 years) ). 
2.3 Type 1 diabetes genetic risk score measurement 
T1D-GRS was generated using 30 single gene polymorphisms (SNPs) as 
previously described (10). Briefly, the score was computed using the number of 
risk alleles across 30 common T1D single nucleotide polymorphisms (SNPs), 
with variants from both HLA and non-HLA loci. They were selected based on 
variants that were strongly associated with T1D as described in existing studies. 
Each variant was weighted based on their effect on T1D genetic risk from 
previous literature. A GRS was generated as the sum across SNPs of the 
number of risk increasing alleles (0, 1 or 2) at that SNP multiplied by the ln(odds 
ratio) for each allele divided by the number of alleles (10). The HLA-DR3 and 
HLA-DR4 haplotypes were weighted using imputed haplotypes. The sum of the 
score signifies a person’s risk for T1D. Genotyping of SNPs was performed 
using the KASP assay by LGC Genomics (Hoddesdon, UK). 
2.4 C-peptide measurement 
C-peptide analysis was performed on the Roche Modular Analytics E170 
immunoassay analyser (Roche Diagnostics, Mannheim, Germany). An antigen-
antibody-antigen sandwich complex was formed by reacting one biotinylated 
anti-C-peptide specific monoclonal mouse antibody and a second monoclonal 
antibody to Cpeptide labelled with a ruthenium complex with 20uL serum 
sample of C-peptide. Separation is achieved via interaction of biotin and 
streptavidin attachment to paramagnetic microparticles (solid phase). The 
detection system employs electrochemiluminescence with ruthenium 
trisbipyridyl as the label. Electrochemiluminescence occurs at 620 nm and 
readings are taken by the photomultiplier tube (PMT). The intensity of light 
signal is proportional to the concentration of C-peptide in the serum. The assay 
was calibrated using Roche C-peptide CalSet calibration material (Roche 
Diagnostics, Mannheim, Germany), traceable to WHO International Reference 
Reagent (IRR) for C-peptide of human insulin for immunoassay (IRR code 
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84/510) (11). Quality Control was performed on each day of analysis using low 
level (67 pmol/L) and high level (3.33 pmol/L) PreciControl MultiAnalyte. 
2.5 MODY genetic sequencing 
Genomic DNA was extracted from whole blood using standard procedures and 
the promoter, all coding regions and intron/exon boundaries of the GCK, 
HNF1A and HNF4A genes were amplified by PCR. Amplicons were sequenced 
using the Big Dye Terminator Cycler Sequencing Kit v3.1 (Applied Biosystems, 
Warrington, UK) according to manufacturer’s instructions and reactions were 
analysed on an ABI 3730 Capillary sequencer (Applied Biosystems, Warrington, 
UK). Sequences were compared with the reference sequences (NM_000162.4 
for GCK, NM_000545.6 for HNF1A and NM_175914.4 for HNF4A) using 
Mutation Surveyor v5.0.1 software (SoftGenetics, State College, PA). 
2.6 Statistical analysis 
Islet autoantibody positivity rates were compared between patient groups. 
Fisher’s exact test was used to determine the effect of single antibodies in 
differentiating non-MODY from MODY.  C-peptide and T1D-GRS levels were 
also compared between patient groups, with data presented as median and 
interquartile range (IQR). Mann-Whitney U-test was used to determine 
statistical significance between C-peptide and T1D-GRS levels as they are not 
normally distributed, determined by the Shapiro-Wilk’s test. Data was cleaned 
using Stata Statistical Software: Release 14. (College Station, TX: StataCorp 
LLC). Statistical analysis was performed using RStudio (RStudio, Inc., Boston, 
MA) and the creation of graphs was performed using ggplot2 package within 
RStudio (12). 
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3 - Results 
3.1 Patients characteristics 
834 consecutive patients were referred to the Exeter molecular genetics service 
between 2012 to 2015. 188 (23%) of participant had a genetic diagnosis of 
MODY (78 GCK, 65 HNF1a, 29 HNF4a, 11 HNF1b), and 646 (77%) of patients 
with no genetic cause found (non-MODY). Baseline characteristics were 
different between non-MODY and MODY patients, with MODY patients being 
younger (median 25 vs 18 years, p < 0.0001), a lower BMI (median 24.8 vs 
23.05 kg/m2, p < 0.0001), and a lower Hba1c (median 62 vs 50 mmol/mol, p < 
0.0001) at diagnosis. Although non-MODY patients generally had a longer 
disease duration compared to MODY patients before they were diagnosed, this 
was not statistically significant (median 3 vs 2 years, p = 0.48). Further clinical 
characteristics are shown in table 1.  
 
 
non-MODY MODY 
n 646 188 
Female (n) 336 (55%) 111 (61%) 
BMI (kg/m2) 25 (22 – 29) 23 (20 – 27) 
Age at diagnosis (years) 25 (16 – 34) 18 (14 – 25) 
Disease duration (years) 3 (1 - 9) 2 (0 – 12) 
Hba1c (mmol/L) 62 (48 – 84) 50 (44 – 60) 
Exeter MODY Probability Score 33 (6 – 58) 75 (46 – 76) 
Patients on insulin (n) 239 (37%) 28 (15%) 
Patients on Oral Hypoglycaemic Agent (OHA) 74 (11%) 62 (33%) 
Patients on Insulin and OHA treated (n) 49 (8%) 4 (2%) 
Patients on Diet Treatment (n) 40 (6%) 20 (11%) 
Table 1: Clinical characteristics of patient cohort in this study. Results are in median 
with the interquartile range (IQE) in parentheses unless stated otherwise. 
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3.2 Differentiating MODY from non-MODY  
3.2.1 Islet autoantibodies 
Islet autoantibodies were able to exclude 21% patients from unnecessary 
MODY genetic testing. A total of 135/646 (20.9%) non-MODY patients had 
positive islet autoantibodies (Figure 1). Overall, the combination of GADA and 
IA-2A excluded 18.9% of patients from genetic testing. ZnT8A along with GADA 
and IA-2A excluded an additional 1.4% of patients from genetic testing. ZnT8A 
increased to number of patients from single to multiple antibody positivity by 
3.3% (p < 0.0001). The autoantibody positivity rates in non-MODY patients 
increased to 32.2% in a sub-analysis of patients who were on insulin treatment, 
i.e, 1 in 3 non-MODY patients could have been excluded from MODY genetic 
testing. Islet autoantibodies were also able to exclude 14.3% of non-insulin 
treated patients from genetic testing. Interestingly, non-MODY patients within 
this group had a median disease duration of 1.5 years (IQE 0 – 5 years). Table 
of antibody positivity between both groups are shown in table 2. Only 1/188 
(0.5%) MODY patient was found to be positive to ZnT8. The area under the 
receiver operator curve (ROC-AUC) for combined islet antibodies was 0.6013. 
 
 non-MODY MODY 
 Insulin treated Non-insulin treated Insulin treated Non-insulin treated 
Figure 1: (A) Stacked bar chart showing percentage of antibody positivity between non-MODY 
and MODY patients. (B) Stacked bar chart showing percentage of antibody positivity between 
insulin treated non-MODY and MODY patients. 
Table 2: Number of patients with positive islet autoantibodies, split by disease and 
treatment status. 
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GADA only 22 12 0 0 
IA-2A only 27 14 0 0 
ZnT8A only 6 7 1 0 
GADA+IA-2A 5 8 0 0 
IA-2A+ZnT8A 5 6 0 0 
GADA+ZnTA 6 4 0 0 
All Three antibodies 6 7 0 0 
No antibody 162 349 27 160 
Clinicians notified the genetic service on the referral form if a patient had routine 
islet autoantibodies measured prior to their referral. A total of 314/646 (48.6%) 
non-MODY patients and 74/188 (39.4%) MODY patients had islet antibodies 
measured externally. Out of these patients, 101/646 (15.6%) non-MODY 
patients had positive GAD and IA2 autoantibodies. No patients had ZnT8A 
measured prior to their referral. In addition, no MODY patients had positive islet 
autoantibodies prior to referral. 
 
 
3.2.2 C-peptide diagnostic utility 
There is a slight decrease in C-peptide levels in patients as disease duration 
lengthens (Figure 2). However, there was no difference in C-peptide levels 
between non-MODY patients compared to MODY patients at referral (median 
564 pmol/L, Interquartile range (IQR) 280 – 958 pmol/L vs 483, 285 – 752, p = 
0.08). There was low diagnostic utility in using C-peptide to differentiate non-
MODY from MODY patients, with the area under the receiver operator curve 
(ROC-AUC) of 0.53 (Figure 3). In a sub-analysis of patients who were on insulin 
treatment, C-peptide levels remained similar between non-MODY and MODY 
patients, with higher median C-peptide levels in MODY patients compared to 
non-MODY patients without statistically significance and low diagnostic utility 
(median 262 pmol/L, IQR 79 – 553 pmol/L, vs 251, 181 – 451, p = 0.55, ROC-
Figure 2: (A) Scatterplot showing C-peptide levels against disease duration in non-MODY 
patients. (B) Scatterplot showing C-peptide levels against disease duration in MODY patients.  
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AUC =0.54). 
‘ 
 
3.2.3 Type 1 genetic risk score diagnostic utility 
T1D-GRS was not useful in differentiating between non-MODY and MODY 
patients at referral. The median T1D-GRS in non-MODY patients was higher 
compared to MODY patients with statistical significance (median 0.24, IQR 0.22 
– 0.27, vs 0.23, 0.22 – 0.25, p = <0.0001), however the diagnostic utility of T1D-
GRS in differentiating non-MODY from MODY patients was modest (ROC-AUC 
= 0.62) (Figure 3). Results remained similar in a sub-analysis of patients who 
were on insulin treatment, with statistically significant T1D-GRS but low 
diagnostic utility in differentiating non-MODY patients from MODY patients 
(median 0.26, IQR 0.23 – 0.28 vs 0.24, 0.22 – 0.26, p = 0.01, ROC-AUC = 
0.65.) 
 
 
 
Figure 3: (A) Boxplot showing C-peptide levels between non-MODY and MODY patients. 
(B) ROC graph of C-peptide with AUC.  
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3.3 - Combined biomarker utility 
Due to the strength of islet autoantibodies in differentiating non-MODY patients 
from MODY patients, we investigated whether C-peptide and / or T1D-GRS 
provided further diagnostic discrimination in patients with negative islet 
autoantibody tests. Overall, C-peptide and T1D-GRS did not provide additional 
diagnostic discrimination in antibody negative patients. C-peptide levels were 
higher in non-MODY patients compared to MODY with statistical significance 
(median 618, IQR 340 – 1020 vs 480 (285 – 752) pmol/L, p = 0.0008), however 
there was very little diagnostic utility (ROC-AUC = 0.6016) above islet 
antibodies. Similarly, there was no additional diagnostic utility in insulin treated 
antibody negative patients (median 399 pmol/L, IQR 135 – 670 pmol/L vs 251 
pmol/L , 181 – 451 pmol/L, p = 0.48, ROC-AUC = 0.5727). 
T1D-GRS levels were comparable between non-MODY patients and MODY 
patients with modest statistical significance and did not provide further 
diagnostic utility (0.23 (0.22 – 0.26) vs 0.23 (0.22 – 0.25), p = 0.02, ROC AUC = 
0.57). Likewise, in insulin treated antibody negative patients, GRS levels and 
diagnostic utility remained similar with no additive diagnostic benefit (0.24 (0.22 
– 0.27) vs 0.24 (0.22 – 0.26), p = 0.25, ROC AUC = 0.58). 
Figure 4: (A) Histogram showing T1D-GRS levels between non-MODY and MODY patients 
(B) ROC graph of T1D-GRS with AUC. 
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4 - Discussion 
The results of this study shows that islet autoantibodies can be used to 
rationalise genetic testing for MODY. We found that the combination of GADA, 
IA-2A, and ZnT8A were able to exclude up to 21% of patients from MODY 
genetic testing, which increases to 32% if islet autoantibodies were measured in 
patients who were on insulin treatment. Although the additional benefit of 
ZnT8A in identifying patients who were previously antibody negative was small, 
it modestly increased the number of patients who were single autoantibody 
positive to multiple antibody positivity. This decreases the probability of MODY 
and increases our confidence in excluding patients from MODY genetic testing. 
In addition, despite the fact that the net discrimination of islet autoantibody was 
not high, with a ROC-AUC of 0.6013, islet autoantibodies still has good negative 
predictive value, as islet autoantibody positive rates in MODY patients are low. 
The islet autoantibody positive rates in non-MODY patients was lower 
compared to previous studies. This is possibly due to the fact that the cohort 
referred to the Exeter genetics referral service represent a very atypical group 
of patients with young onset diabetes. They have been identified by their 
clinicians as having feature that may be indicative of MODY, including 
assessment of islet autoantibodies and C-peptide in some cases. Therefore, 
there would be a mixture of T1D and T2D patients within the non-MODY cohort. 
The lower positive rates of islet autoantibodies could also be explained by the 
fact that islet autoantibodies were not measured close to diagnosis in a 
proportion of patients within this cohort, since the positive rates of islet 
autoantibodies decreases as disease duration lengthens. This would also 
explain the lower positive rates of ZnT8A compared to GADA and IA-2A within 
this cohort, as the positive rate of ZnT8A seems to decrease more over time 
compared to the two established autoantibodies. Nonetheless, islet 
autoantibodies were still able to exclude 20 to 30% of patients from MODY 
genetic testing. Interestingly, in a sub-analysis of patients who were not on 
insulin treatment, islet autoantibodies were also able to exclude 14% of patients 
from MODY genetic testing. This shows that islet autoantibodies can be used as 
a biomarker to rationalise genetic testing. 
We did not find additional diagnostic utility of C-peptide in ruling out patients 
from MODY genetic testing in the referral setting. Levels of C-peptide were not 
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statistically different between non-MODY and MODY patients, and the ROC-
AUC was too low to use as a rule out test, even in those who were insulin 
treated. This may highlight the fact that non-MODY patients that were referred 
to the genetics service were predominately patients with type 2 diabetes. 
Evidence of this included more non-MODY patients being on oral 
hypoglycaemic agents or diet treatment with longer disease duration, and 
relatively low levels of islet autoantibodies. 
T1D-GRS did not perform as well as what we described in the referral setting. 
Previously, we found that T1D-GRS showed discriminative power between 
MODY and T1D patients, with scores being higher in patients with T1D 
compared to MODY patients with relatively good diagnostic utility (ROC-AUC = 
0.87), which was in contrast to the results in this study. Although T1D-GRS was 
statistically higher in non-MODY patients compared to MODY patients within 
this study, there was a lack of diagnostic utility when the cohort was compared 
as a whole. It was possibly due to the fact that our previous study was done in a 
case control setting, with T1D-GRS of pre-selected patients having a T1D 
phenotype (diagnosed under 17 years of age, insulin treated and islet 
autoantibody positive) compared to patients with MODY, whereas the cohort 
within this study consists of a mixed population of T1D, T2D and MODY. It is 
also important to note that the mean T1D-GRS in MODY patients in our 
previous paper was 0.231, which was identical to the results seen in MODY 
patients within this cohort. However, the mean T1D-GRS of patients with T1D 
previously described was 0.279, which was significantly higher compared to the 
scores of non-MODY patients within this study. This highlights the 
heterogeneous group of patients that were referred to our genetics service, 
reiterating the fact that there was a mixture of patients with T1D and T2D within 
the non-MODY group. In addition, by comparing non-MODY patients who were 
phenotypically similar to T1D (in accordance with Royal College of General 
Practitioners Diabetes Classification guidance) with MODY patients within this 
study, the diagnostic utility of T1D-GRS increases, with a ROC-AUC of 0.75.  
This is to our knowledge the first study which investigated whether biomarkers 
were useful in rationalising genetic testing in the referral setting. Novel 
biomarkers in differentiating non-MODY and MODY patients were also 
investigated, namely ZnT8 autoantibodies in combination with established islet 
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autoantibodies and the T1D-GRS. Whilst most studies that investigated the use 
of islet autoantibodies in differentiating non-MODY patients from MODY patients 
were done retrospectively or presented in case studies (7, 13-16), this study 
was done prospectively in the referral setting. This study also contained the 
largest cohort of patients referred prospectively for MODY genetic testing. In 
addition, serum sent to the genetics service was analysed within a single 
laboratory and all patients had standardised genetic testing. The islet 
autoantibody reference ranges were derived from a control population, making 
the results more reliable. Clinicians also notified the genetics service on referral 
forms if they were previously screened for islet autoantibodies prior to their 
referral, and patients were not excluded on the basis of positive autoantibodies 
to minimise bias.  
There were several limitations to our study. The study looked at classical 
MODY, namely GCK, HNF1a, HNF4a and HNF1b. However, the study did not 
take into account whether islet autoantibodies and biomarkers were able to 
exclude patients from classical forms of other less common forms of monogenic 
diabetes, such as INS and Peroxisome proliferator-activated receptor gamma 
(PPARG) mutations, which were excluded from the study. Secondly due to the 
nature of the referral service, there were low numbers of MODY patients who 
were treated with insulin when they were referred, meaning we could be 
underestimating the discriminative power of C-peptide and T1D-GRS in insulin 
treated patients within this study. However, there was significant overlap of C-
peptide distributions between non-MODY and MODY patients, meaning that C-
peptide levels would not be significantly higher even if we increased the number 
of insulin treated MODY patients within the sub-analyses. 
Islet autoantibodies represents a cost effective way in ruling out patients from 
genetic testing, as a triple antibody test cost £27 compared to £700 for targeted 
capture. This meant the service could have saved £90855 by rationalising 
genetic testing using islet autoantibodies. Based on these result, we believe all 
three islet autoantibodies should be measured in all patients who would be 
referred to the service for genetic testing. The results here can also be applied 
to other MODY referral centres. More studies are required to investigate 
whether islet autoantibodies, C-peptide and T1D-GRS is useful in the setting of 
a diabetes clinic in secondary care. 
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In conclusion, we have shown that the combination of GADA, IA-2A and ZnT8A 
were able to exclude 20-30% of patients from MODY genetic testing in the 
referral setting. C-peptide and T1D-GRS were not additive on top of islet 
autoantibodies in excluding patients from genetic testing. As the measurement 
of islet autoantibodies was a cost effective way of rationalising genetic testing, it 
would be embedded in the diagnostic pathway at the genetics referral service in 
Exeter.  
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Discussion 
This thesis assessed the diagnostic utility of zinc transporter 8 (ZnT8) 
autoantibodies compared to autoantibodies against glutamic acid 
decarboxylase (GADA) and protein tyrosine phosphatase islet antigen-2 (IA-2A) 
in discriminating type 1 diabetes (T1D) from Maturity Onset Diabetes of the 
Young (MODY). This thesis also investigated whether islet autoantibodies, 
Connecting peptide (C-peptide) and the type 1 diabetes genetic risk score 
(T1D-GRS) are useful in rationalising genetic testing in the prospective referral 
setting by ruling patients out for MODY genetic testing. 
This chapter provides a discussion of the findings of previous chapters, 
implications, strength and limitations, along with plans for future research. 
Chapter 1: The addition of Zinc Transporter 8 autoantibodies to 
established islet autoantibodies improves discrimination of MODY 
from T1D close to diagnosis 
It had been shown that the prevalence of GADA and IA-2A were low in patients 
with MODY, with a prevalence of <1% within MODY patients, similar to non-
diabetic controls (1). However, ZnT8A had never been studied in this context as 
it was a relatively novel biomarker for T1D compared to established 
autoantibodies GADA and IA-2A. Studies investigating ZnT8A were mainly 
performed in the context of T1D diagnosis and classification, and not its 
discrimination of T1D from MODY (2–4). Furthermore, the previous paper also 
only studied patients close to diagnosis, and did not investigate the effects of 
disease duration on the prevalence and discriminative power of islet 
autoantibodies. 
The aim of this chapter was to determine the prevalence of ZnT8A in relation to 
established islet autoantibodies GADA and IA-2A in patients with T1D 
compared to patients with MODY. The discriminative power of ZnT8A in 
differentiating T1D from MODY and whether ZnT8A offered additive 
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discriminatory effects along with GADA and IA-2Awas studied. Lastly, the effect 
of disease duration on prevalence and discriminative power of all three 
autoantibodies was also studied. 
Main result: 
ZnT8A were able to discriminate T1D patients from MODY independently, with 
sensitivity and specificity comparable to GAD and IA-2A. The results here show 
that the prevalence of ZnT8A in MODY patients were similar to non-diabetic 
control, at a level of 1% in concordance with the prevalence of GADA and IA-
2A. Although ZnT8A only modestly increased the number of patients who were 
previously antibody negative to single antibody positivity, they were able to 
significantly increase the number of patients who were previously positive for 
single antibody to multiple antibody positivity.  
Islet autoantibody prevalence remains low in patients with MODY, supporting 
the results found in our previous study (1). Around 800 individuals with 
genetically confirmed MODY in both studies had islet autoantibodies assessed 
in our unit, with a consistently low prevalence of islet autoantibodies. This 
reiterates the fact that biomarkers of autoimmunity do not form part of the 
disease process in MODY. This has also been supported by case reports and 
family studies (5–7). A study based on cohorts within a German and Austrian 
registry with MODY showed an autoantibody prevalence of 17% within MODY 
patients, although the study did not publish details on islet autoantibody assays 
or the reference range thresholds used. The study also defined MODY using 
clinical features (non‐insulin‐dependent diabetes with no or unexpectedly low 
insulin requirement and the absence of signs of insulin resistance such as 
acanthosis nigricans or marked obesity) and did not confirm the diagnosis of 
MODY using a genetic test in up 20% of the patients (8). It is possible that the 
patients defined as MODY had T1D, which may explain the higher prevalence 
of islet autoantibodies. 
Islet autoantibodies achieved the highest diagnostic utility in discriminating T1D 
from MODY when they were measured closer to diagnosis. This is due to the 
decreasing prevalence of all three islet autoantibodies in patients with T1D as 
disease duration increased. This is most evident in ZnT8A and IA-2A, although 
a drop in prevalence was also seen in GADA. In patients with the longest 
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disease duration at 22 years, ZnT8A prevalence was evidently lower compared 
to GADA and IA-2A. Previously, studies suggested that islet autoantibody levels 
were highest within patients with young onset T1D, and cross-sectional analysis 
of showed that autoantibody levels decreased over time, possibly due to a 
weaning of autoimmunity (9). This may be explained by the decrease of the 
overall number of antigens present within the beta cell over time, associated 
with the lowering number of beta cells. However, this does not necessarily 
explain the difference between the types of autoantibody as their prevalence 
seem to vary at different time points. 
Clinical Implications 
The results of this chapter suggests that islet autoantibodies should be used as 
a test while investigating patients with a suspected diagnosis of MODY, with 
ZnT8A autoantibodies measured in addition to GADA and IA-2A. Since the 
increasing number of positive islet autoantibodies decreases the probability of a 
MODY diagnosis, islet autoantibodies could be considered as a “ruling out” test 
for patients with suspected MODY. A single positive islet autoantibody test in a 
patient with suspected MODY warrants further clinical investigations before 
molecular genetic testing. However, if the patient is positive for multiple 
autoantibodies, genetic testing should not be performed since the probability of 
a MODY diagnosis would be very low. 
In addition, based on the results from this chapter, islet autoantibodies should 
be measured as close to diagnosis as possible if MODY is suspected. The 
falling of islet autoantibody prevalence affects its discriminatory power in 
differentiating T1D from MODY, as less T1D patients were positive for 
autoantibodies. Although islet autoantibodies would also be useful in patients 
with longer disease duration, it is important to acknowledge that the 
discriminative power of islet autoantibody decreases over time.  
Strength and limitations: 
This is the first study which investigated the prevalence of ZnT8A in MODY 
patients, with comparisons made between GADA and IA-2A. The sera used 
within this study was analysed in a single laboratory, and the antibody reference 
ranges were derived from a standard control population, making reference 
thresholds more robust. Finally, as mentioned above, the study investigated a 
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large cohort of MODY patients and T1D patients, allowing the examination of 
duration effects on the prevalence of islet autoantibodies. 
Several limitations exist within this study, including the study design and the 
study method. This study was performed as a retrospective case control study, 
meaning prospective data on patients were unavailable. Patient groups, 
especially patients with T1D, were pre-selected and pre-defined before they 
were analysed within the study cohort due to the design of the study. We were 
also unable to select patients within the IASP cohort based on insulin 
requirement, as anonymised samples were sent to our laboratory for the 
programme. The study of disease duration and its effects on islet 
autoantibodies prevalence and discriminative power was based on a cross-
sectional analysis across the study cohort, meaning we were unable to study 
the effect of disease duration in the same patients as longitudinal data is 
unavailable.  
Lastly, the possibility that patients within this cohort were pre-screened for 
antibodies before they were referred to our genetic laboratory could not be 
excluded, which could explain the low prevalence in our study group. However, 
if the analysis within this study was restricted to only probands (n = 183) who 
previously were not screened for autoantibodies, the antibody prevalence rate 
was 0.01%, lower than the expected prevalence in control populations. 
Future areas of research 
As this study was performed as a retrospective case control study, it would be 
important to investigate whether islet autoantibodies remains useful in the 
prospective referral setting. Other biomarkers, such as C-peptide and the T1D-
GRS, should also be investigated, as previous case control studies suggested 
their use as a ruling out test similar to islet autoantibodies (10,11). It would also 
be of interest to recruits patients with a newly diagnosed diabetes with annual 
assessment of islet autoantibodies to investigate the rate of change that occurs 
with disease duration and compared this with MODY patients matched by the 
same disease duration. 
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Chapter 2: Islet autoantibodies are useful in rationalising genetic 
testing for MODY in a NHS genomics laboratory referral pipeline 
ZnT8A in addition with GADA and IA-2A had been shown to be useful in 
discriminating T1D from MODY in the case control setting, as shown in Chapter 
3. However, the diagnostic utility of islet autoantibodies in a referral setting had 
never been studied. It is important to determine this as the results would affect 
the referral pipeline at the Exeter molecular genetics service, which is a national 
referral centre for MODY and receives around 1000 referrals for MODY testing 
each year. Islet autoantibodies can be used as a way to rationalise genetic 
testing at the referral service by excluding patients from testing due to the costs 
associated with genetic testing. 
In addition, other biomarkers such as Connecting peptide (C-peptide) and the 
Type 1 diabetes genetic risk score (T1D-GRS) had been previously shown to 
have some use in differentiating T1D from MODY patients (1). However, this 
had never been studied in the context of the referral setting, and studies were 
mainly performed in a retrospective case control analysis.  
The aim of this chapter was to determine whether islet autoantibodies were able 
to exclude patients from MODY genetic testing in a consecutive patient cohort 
as a way to rationalise genetic testing. This chapter also aimed to investigate 
whether there was any diagnostic value with C-peptide and T1D-GRS in ruling 
out patients from MODY genetic testing in the referral setting. 
Main Result 
In this study, we found that islet autoantibodies were able to exclude 21% of 
patients from MODY genetic testing, meaning that 1 in 5 patients could have 
avoided genetic tests. This percentage increased in patients who were on 
insulin treatment to 33%. Although the additional benefit of ZnT8A in identifying 
individuals who were previously antibody negative was small, it modestly 
increased the number of patients who were single autoantibody positive to 
multiple antibody positivity. This increases our confidence in excluding patients 
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from genetic testing, as the increasing number of positive antibodies decreases 
the probability of MODY. Important to note that clinicians refer patients with an 
atypical presentation of diabetes, such as a patient with a T1D phenotype and 
not requiring a standard dose of insulin, which means that the study cohort may 
have a mix of patients with T1D, T2D and MODY. Even so, islet autoantibodies 
were able to exclude 20-30% of patients from MODY genetic testing. 
Interestingly, islet autoantibodies could have excluded close to 15 of non-insulin 
treated non-MODY patients from genetic testing (oral hypoglycaemic agent or 
diet treated). Inaccuracies in referral forms sent to the genetic service may 
explain this, with clinicians entering incorrect treatment data into referral forms. 
This means that some patients could be incorrectly classed as non-insulin 
treated due to clinician error. Alternatively, this result could also be explained by 
the mixed cohort of patients referred to the genetics referral service. Patients 
within the honeymoon period of T1D may require variable amounts of insulin as 
they continue to have a decreasing number of functioning beta cells. However, 
they would have measurable islet autoantibodies at this time as this reflects the 
underlying autoimmune processes leading to beta cell dysfunction. Therefore, 
this may affect a clinician’s decision in referring a patient to the Molecular 
genetics service. The level of islet autoantibodies is lower in this study 
compared to the results in the previous chapter since the cohort of non-MODY 
patients are not pre-selected to fit a T1D criteria, with a possibility of a 
predominance of patients with T2D within the non-MODY group. This may be 
supported by the fact that more non-MODY patients were on oral 
hypoglycaemic agents or diet treatment with longer disease durations.  
C-peptide did not provide further diagnostic value in excluding patients from 
MODY genetic testing. It is thought that persistent C-peptide is an important 
clinical feature in the diagnosis of MODY (12). C-peptide reflects endogenous 
insulin secretion, as it is cleaved to from proinsulin to form insulin in a 1:1 ratio 
(13). Theoretically, C-peptide levels would be lower in patients with T1D 
compared to MODY, due to endogenous insulin deficiency associated with T1D. 
The level of C-peptide was not significantly different between non-MODY and 
MODY groups within this study. The area under the receiver-operator curve 
(ROC-AUC) was also very low (ROC-AUC = 0.53) to justify its use in the referral 
setting. This may be due to the fact that a majority of patients in the non-MODY 
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group had T2D. C-peptide levels between patients with T2D and MODY would 
be similar since endogenous insulin production would be present in both 
conditions, unlike T1D. A sub-analysis of C-peptide levels in patients on insulin 
treatment was performed, however, levels of C-peptide between both groups 
remained similar with a lack of diagnostic utility. 
Like C-peptide, T1D-GRS was not additive in ruling out patients from MODY 
genetic testing. It was found previously that T1D-GRS can discriminate between 
patients with MODY and T1D. Previous studies showed that T1D has a strong 
genetic component, and a score was generated as a way to quantify a person’s 
genetic risk of T1D, based on single nucleotide polymorphisms (SNPs) 
genotyping data (10). As expected, the T1D-GRS was higher in patients with 
T1D compared to MODY with good diagnostic utility (ROC-AUC = 0.87) (11). 
However, that was shown in a case control setting with pre-defined study 
groups. In this study, although T1D-GRS was statistically higher in non-MODY 
patients compared to MODY patients, diagnostic utility was not achieved, with a 
ROC-AUC of 0.62 Similar to C-peptide, this results remained the same in a sub-
analysis of patients on insulin treatment, with a modest gain of diagnostic utility 
(ROC-AUC = 0.65). Again, this highlights the heterogeneous group of patients 
referred to the genetic service. 
Clinical Implications 
Currently, a clinical features based approach is used to rationalise genetic 
testing i.e a clinical scientist / geneticist decides whether a patient has genetic 
testing based on clinical experience and judgement. Islet autoantibodies are 
only measured on patients who are on insulin treatment since insulin 
requirement is associated with T1D and islet autoantibodies would likely be 
positive before genetic testing is performed. Given that non-insulin treated 
patients also had positive islet autoantibodies, the results from this chapter 
suggest that all patients should receive islet autoantibody testing regardless of 
their clinical features. This approach would be able to capture all patients 
referred regardless of treatment status and would also eliminate some human 
biases when rationalising genetic testing at the referral service. Islet 
autoantibodies are also a cost effective way to rationalise genetic testing. Since 
a triple antibody test (GAD, IA2 and ZnT8) cost £27 compared to £700 for 
targeted capture genetic testing, meaning that the service could save £90855 
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by rationalising genetic testing using islet autoantibodies based on this patient 
cohort. 
The results from this chapter also suggest that serum C-peptide measurement 
and the T1D-GRS should not be used in the genetic referral service. The test 
does not provide additional benefit as a ruling out test compared to islet 
autoantibodies in the referral service. Whether these tests are useful in the 
setting of a clinic has yet to be elucidated. 
Strength of study 
This is the first study that investigated whether islet autoantibodies, C-peptide 
and T1D-GRS have diagnostic utility in ruling out patients from MODY genetic 
testing in the referral setting. The use of novel biomarkers ZnT8A and the T1D-
GRS were also investigated. This study was also performed in the prospective 
referral setting, which studied a large cohort of patients referred prospectively 
for MODY genetic testing. In addition, all patients within this cohort had 
standardised genetic testing (GCK, HNF1a and HNF4a genes sequences), and 
sera were analysed in a single laboratory. 
Limitations and Future areas of research 
Due to the nature of the referral service, there were low numbers of MODY 
patients treated with insulin when they were referred, meaning the study could 
be underestimating the discriminative power of C-peptide and T1D-GRS in sub-
analyses of insulin treated patients within this study. This was mainly due to 
some clinicians not providing treatment data on referral forms when their 
patients were referred.  In order to capture data from every patient referred to 
the genetic service, an electronic referral form with mandatory fields should be 
created, where clinicians have to input a minimum amount of data before the 
referral form can be sent to the genetic service. This would be beneficial for 
both research purposes and the running of the genetics service. It would also 
be useful to investigate whether the data from the electronic referral forms could 
be transferred directly into the electronic patient database held at the genetic 
service. This would minimise issues with missing data within the database and 
reduce human error when transferring patient data from the current paper 
referral forms in to the patient database.  
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This study did not investigate whether biomarkers, especially islet 
autoantibodies, were able to exclude patients from genetic testing compared 
against rarer forms of monogenic diabetes, such as conditions caused by 
mutations to the INS or Peroxisome proliferator-activated receptor gamma 
(PPARG) genes. It would be of interest to look at the prevalence of islet 
autoantibodies in patients with rare forms of MODY referred to the genetic 
service compared to patients without a genetic diagnosis to see if islet 
autoantibodies retain its clinical utility. In addition, since this study was 
performed in the context of the referral setting, the results may not represent 
what happens in the setting of a diabetes clinic. Biomarkers investigated within 
this study may perform differently due to the difference in patient presented in 
the clinic setting. A study can be performed to look at a cohort of patients with 
newly diagnosed diabetes (T1D or T2D) with biomarkers measured and 
compared to newly diagnosed genetically confirmed MODY patients. 
Although serum C-peptide was not useful within this study in discriminating non-
MODY from MODY patients, it would be of interest to investigate the diagnostic 
utility of urine C-peptide : Creatinine ratio as a rule out test in the referral 
setting, as case control studies have suggested that the test has clinical utility in 
the diagnosis of MODY (14,15).  
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